Serum vitamin D level is associated with disease severity and response to ursodeoxycholic acid in primary biliary cirrhosis

Alimentary Pharmacology and Therapeutics

Volumn 42, Issue 2, 2015, Pages 221-230

  Guo, G Y ^a,b   Shi, Y Q ^a,b   Wang, L ^a,b   Ren, X ^a,b   Han, Z Y ^a,b   Guo, C C ^a,b   Cui, L N ^a   Wang, J B ^a   Zhu, J ^a   Wang, N ^a,b   Zhang, J ^a,b   Cai, Y ^a,b   Han, Y ^a,b   Zhou, X M ^a,b   Fan, D M ^a,b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ALKALINE PHOSPHATASE; BILIRUBIN; URSODEOXYCHOLIC ACID; 25-HYDROXYVITAMIN D; CHOLAGOGUE; VITAMIN D;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT DURATION; TREATMENT RESPONSE; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; AGED; ANALOGS AND DERIVATIVES; BLOOD; COMPLICATION; LIVER CIRRHOSIS, BILIARY; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

ADULT; AGED; ALKALINE PHOSPHATASE; CHOLAGOGUES AND CHOLERETICS; FEMALE; HUMANS; LIVER CIRRHOSIS, BILIARY; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; URSODEOXYCHOLIC ACID; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84931567205     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13244     Document Type: Article

References (44)

1. Hirschfield GM, Gershwin ME,. The immunobiology and pathophysiology of primary biliary cirrhosis. Ann Rev Pathol 2013; 8: 303-30.
2. Lindor KD, Gershwin ME, Poupon R, et al,. Primary biliary cirrhosis. Hepatology 2009; 50: 291-308.
3. Boberg KM, Wisloff T, Kjollesdal KS, Stovring H, Kristiansen IS,. Cost and health consequences of treatment of primary biliary cirrhosis with ursodeoxycholic acid. Aliment Pharmacol Ther 2013; 38: 794-803.
4. Corpechot C, Abenavoli L, Rabahi N, et al,. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 2008; 48: 871-7.
5. Pares A, Caballeria L, Rodes J,. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. Gastroenterology 2006; 130: 715-20.
6. Kumagi T, Guindi M, Fischer SE, et al,. Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis. Am J Gastroenterol 2010; 105: 2186-94.
7. Kuiper EM, Hansen BE, de Vries RA, et al,. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology 2009; 136: 1281-7.
8. Wagonfeld JB, Nemchausky BA, Bolt M, Horst JV, Boyer JL, Rosenberg IH,. Comparison of vitamin D and 25-hydroxy-vitamin-D in the therapy of primary biliary cirrhosis. Lancet 1976; 2: 391-4.
9. Herlong HF, Recker RR, Maddrey WC,. Bone disease in primary biliary cirrhosis: histologic features and response to 25-hydroxyvitamin D. Gastroenterology 1982; 83 (1 Pt 1): 103-8.
10. Hodgson SF, Dickson ER, Wahner HW, Johnson KA, Mann KG, Riggs BL,. Bone loss and reduced osteoblast function in primary biliary cirrhosis. Ann Intern Med 1985; 103 (6 Pt 1): 855-60.
11. Matloff DS, Kaplan MM, Neer RM, Goldberg MJ, Bitman W, Wolfe HJ,. Osteoporosis in primary biliary cirrhosis: effects of 25-hydroxyvitamin D3 treatment. Gastroenterology 1982; 83 (1 Pt 1): 97-102.
12. Eastell R, Dickson ER, Hodgson SF, et al,. Rates of vertebral bone loss before and after liver transplantation in women with primary biliary cirrhosis. Hepatology 1991; 14: 296-300.
13. Ogura M, Nishida S, Ishizawa M, et al,. Vitamin D3 modulates the expression of bile acid regulatory genes and represses inflammation in bile duct-ligated mice. J Pharmacol Exp Ther 2009; 328: 564-70.
14. Firrincieli D, Zuniga S, Rey C, et al,. Vitamin D nuclear receptor deficiency promotes cholestatic liver injury by disruption of biliary epithelial cell junctions in mice. Hepatology 2013; 58: 1401-12.
15. Ding N, Yu RT, Subramaniam N, et al,. A vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response. Cell 2013; 153: 601-13.
16. Peelen E, Knippenberg S, Muris AH, et al,. Effects of vitamin D on the peripheral adaptive immune system: a review. Autoimmun Rev 2011; 10: 733-43.
17. Ritterhouse LL, Crowe SR, Niewold TB, et al,. Vitamin D deficiency is associated with an increased autoimmune response in healthy individuals and in patients with systemic lupus erythematosus. Ann Rheum Dis 2011; 70: 1569-74.
18. Weinstock-Guttman B, Zivadinov R, Qu J, et al,. Vitamin D metabolites are associated with clinical and MRI outcomes in multiple sclerosis patients. J Neurol Neurosurg Psychiatry 2011; 82: 189-95.
19. Runia TF, Hop WC, de Rijke YB, Buljevac D, Hintzen RQ,. Lower serum vitamin D levels are associated with a higher relapse risk in multiple sclerosis. Neurology 2012; 79: 261-6.
20. Garg M, Rosella O, Lubel JS, Gibson PR,. Association of circulating vitamin D concentrations with intestinal but not systemic inflammation in inflammatory bowel disease. Inflamm Bowel Dis 2013; 19: 2634-43.
21. Mouli VP, Ananthakrishnan AN,. Review article: vitamin D and inflammatory bowel diseases. Aliment Pharmacol Ther 2014; 39: 125-36.
22. Petta S, Camma C, Scazzone C, et al,. Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. Hepatology 2010; 51: 1158-67.
23. Farnik H, Bojunga J, Berger A, et al,. Low vitamin D serum concentration is associated with high levels of hepatitis B virus replication in chronically infected patients. Hepatology 2013; 58: 1270-6.
24. Kwok RM, Torres DM, Harrison SA,. Vitamin D and nonalcoholic fatty liver disease (NAFLD): is it more than just an association? Hepatology 2013; 58: 1166-74.
25. Trepo E, Ouziel R, Pradat P, et al,. Marked 25-hydroxyvitamin D deficiency is associated with poor prognosis in patients with alcoholic liver disease. J Hepatol 2013; 59: 344-50.
26. Ananthakrishnan AN, Cagan A, Gainer VS, et al,. Normalization of plasma 25-hydroxy vitamin D is associated with reduced risk of surgery in Crohn's disease. Inflamm Bowel Dis 2013; 19: 1921-7.
27. Ananthakrishnan AN, Cheng SC, Cai T, et al,. Association between reduced plasma 25-hydroxy vitamin D and increased risk of cancer in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2014; 12: 821-7.
28. Garcia-Alvarez M, Pineda-Tenor D, Jimenez-Sousa MA, Fernandez-Rodriguez A, Guzman-Fulgencio M, Resino S,. Relationship of vitamin D status with advanced liver fibrosis and response to hepatitis C virus therapy: a meta-analysis. Hepatology 2014; 60: 1541-50.
29. Finkelmeier F, Kronenberger B, Koberle V, et al,. Severe 25-hydroxyvitamin D deficiency identifies a poor prognosis in patients with hepatocellular carcinoma-a prospective cohort study. Aliment Pharmacol Ther 2014; 39: 1204-12.
30. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009; 51: 237-67.
31. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: The National Academies Press, 2011.
32. Ludwig J, Dickson ER, McDonald GS,. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A Pathol Anat Histol 1978; 379: 103-12.
33. Webb AR, Kline L, Holick MF,. Influence of season and latitude on the cutaneous synthesis of vitamin D3: exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin. J Clin Endocrinol Metab 1988; 67: 373-8.
34. Cholongitas E, Theocharidou E, Goulis J, Tsochatzis E, Akriviadis E, Burroughs K,. Review article: the extra-skeletal effects of vitamin D in chronic hepatitis C infection. Aliment Pharmacol Ther 2012; 35: 634-46.
35. Eliades M, Spyrou E, Agrawal N, et al,. Meta-analysis: vitamin D and non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2013; 38: 246-54.
36. Kaplan MM, Elta GH, Furie B, Sadowski JA, Russell RM,. Fat-soluble vitamin nutriture in primary biliary cirrhosis. Gastroenterology 1988; 95: 787-92.
37. Phillips JR, Angulo P, Petterson T, Lindor KD,. Fat-soluble vitamin levels in patients with primary biliary cirrhosis. Am J Gastroenterol 2001; 96: 2745-50.
38. Agmon-Levin N, Kopilov R, Selmi C, et al,. Vitamin D in primary biliary cirrhosis, a plausible marker of advanced disease. Immunol Res 2015; 61: 141-6.
39. Lammers WJ, van Buuren HR, Hirschfield GM, et al,. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. Gastroenterology 2014; 147: 1338-49 e5; quiz e15.
40. Chan CW, Tsochatzis EA, Carpenter JR, Rigamonti C, Gunsar F, Burroughs AK,. Predicting the advent of ascites and other complications in primary biliary cirrhosis: a staged model approach. Aliment Pharmacol Ther 2010; 31: 573-82.
41. Mora JR, Iwata M, von Andrian UH,. Vitamin effects on the immune system: vitamins A and D take centre stage. Nat Rev Immunol 2008; 8: 685-98.
42. D'Aldebert E, Biyeyeme Bi Mve MJ, Mergey M, et al,. Bile salts control the antimicrobial peptide cathelicidin through nuclear receptors in the human biliary epithelium. Gastroenterology 2009; 136: 1435-43.
43. Kitson MT, Roberts SK,. D-livering the message: the importance of vitamin D status in chronic liver disease. J Hepatol 2012; 57: 897-909.
44. Dan YY, Lim SG,. Commentary: vitamin D deficiency and liver cancer-cause, effect or myth? Aliment Pharmacol Ther 2014; 39: 1429.